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Abstract
Objective - Whether advances in the management of type 1 diabetes are reducing rates of diabetic ketoacidosis
(DKA) is unclear. We investigated time trends in DKA rates in a national cohort of individuals with type 1
diabetes followed for 14 years, overall and by socioeconomic characteristics.
Research Design and Methods - All individuals in Scotland who were alive with type 1 diabetes and at
least one year old between 2004-01-01 and 2018-12-31 were identified using the national register (N=37939).
DKA deaths and hospital admissions were obtained through linkage to Scottish national death and morbidity
records. Bayesian regression was used to test for DKA time trends and association with risk markers, including
socioeconomic deprivation.
This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American 
Diabetes Association (ADA), publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the 
manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a 
future issue of Diabetes Care in print and online at http://care.diabetesjournals.org.
Results - 30427 DKA admissions, and 472 DKA deaths were observed over 393223 person-years at risk.
DKA event rates increased over the study period (IRR per year=1.058 [1.054-1.061]). Males had lower rates
than females (IRR Male:Female=0.814 [0.776-0.855]). DKA incidence rose in all age groups other than 10-19
year-olds, in whom rates were the highest but fell over the study. There was a large socioeconomic differential
(IRR least:most deprived quintile=0.446 [0.406-0.490]) which increased during follow-up. Insulin pump use or
completion of structured education were associated with lower DKA rates, antidepressant and methadone
prescription were associated with higher DKA rates.
Conclusion - DKA incidence has risen since 2004, except in 10-19 year olds. Of particular concern are the
strong and widening socioeconomic disparities in DKA outcomes. Efforts to prevent DKA, especially in
vulnerable groups, require strengthening.
Introduction
Diabetic ketoacidosis (DKA) is a significant contributor to mortality in type 1 diabetes, and we recently
showed that this acute complication is second only to cardiovascular disease as the most frequent cause
of death below 50 years of age in these individuals (1). DKA events are often precipitated by infection,
acute comorbidites, insulin omission, or substance use disorders (2–4), and occur as a consequence of insulin
deficiency in the context of these precipitating factors. Further established risk factors associated with higher
rates of DKA include insulin pump failure, higher HbA1c, disordered eating, lower socioeconomic status and
depression (5–10).
DKA is a preventable cause of death, and reducing DKA mortality would lower the excess mortality associated
with type 1 diabetes (1,11). Recent studies have suggested that DKA admission rates and the proportion
of people with DKA at diagnosis of type 1 diabetes are increasing (12,13). In addition to this, we recently
reported that DKA mortality rates have not significantly improved in Scotland in recent years for people
below 50 years of age (11). Improving early diagnosis of type 1 diabetes, identification of DKA, and the
reduction of the impact of deprivation on diabetes care and outcomes are key priorities in the Scottish
Government’s Diabetes Improvement Plan (14).
Accurate quantification of DKA event rates and identification of associated risk factors are required to inform
future DKA prevention strategies and health care delivery models. Few studies have quantified DKA event
rates over time in large population representative cohorts (3,5), and even fewer have attempted to estimate
the association of socioeconomic status with these rates. Consequently, identifying the characteristics of
individuals at elevated risk of DKA admission or mortality remains a priority. This current study aimed to
quantify trends in DKA events in a comprehensive nationwide cohort of individuals with type 1 diabetes over
a 14 year period using electronic healthcare records, and to identify the association of socieoeconomic status
with DKA event rates and their associated time trends.
Research Design and Methods
Dataset And Cohort Definition
Scottish Care Information - Diabetes (SCI-Diabetes) is the national disease management system of individuals
diagnosed with any form of diabetes in Scotland , achieving over 99% coverage. This register can be linked to
death data provided by the Information Services Division of NHS Scotland and National Records of Scotland
(NRS). We identified a cohort of all people with a clinical diagnosis of type 1 diabetes who were alive at any
point between 2004-01-01 and 2018-12-31. Clinician assigned diabetes type was accepted unless there was
contradictory prescription historys data. Cohort members contributed data from 2004-01-01 or the date of
their diagnosis with type 1 diabetes, whichever was later, up to date of death during the study period, leaving
the jurisdiction, or the end of the study period. Periods of observability were defined using routine observation
and prescription data. The number of hospital admissions for DKA for each individual were collected from
2
Scottish Morbidity Record (SMR-01) data and DKA mortality data was taken from the Medical Certificate
of Cause of Death (MCCD) for each individual who died during the study period, as provided by NRS. The
presence of an ICD-10 code for DKA (i.e. E10.1, E11.1, E12.1, E13.1, E14.1) anywhere on an admissions
record or MCCD was considered to be a hospital admission or a death with DKA, respectively. We combined
DKA hospital admissions and DKA deaths into a composite count of DKA events experienced for each
individual; this count included both DKA at diagnosis events and any subsequent events.
Statistical Methods
Directly standardised rates of DKA were calculated using the 2011 population structure of people with type 1
diabetes in Scotland as the standard. Bayesian generalised linear regression (GLM) analyses were performed
to estimate the association of a number of covariates with event rates. Each individual’s longitudinal electronic
healthcare record data was time sliced to produce a survival table with each time-slice being a single calendar
year in length. To summarise the results from Bayesian analysis we report median posterior estimates, 95%
credibility intervals (95% CrI), and a measure which is equivalent to a p-value assessed at the posterior
median.
To investigate the association of covariates with recurrent DKA we performed a Bayesian poisson regression
analysis in which the outcome was a binary measure of whether or not an individual experienced more than
one DKA event in a given time slice. To investigate DKA case-fatality we used a Bayesian logistic regression
model in which each DKA event was an observation and the outcome was the fatality status of the DKA
event. If an individual died during a hospital admission with an ICD-10 code for DKA mentioned at any
point on their MCCD, we determined this to be an instance of case-fatality. Similarly, any out-of-hospital
death for which DKA was identified on the MCCD was also considered to be an incidence of case-fatality.
We explored several factors previously reported as being associated with increased risk of DKA (6,9,15,16).
To test the basic association of social deprivation with each DKA outcome we performed a set of minimally
adjusted analyses in which the adjustment covariates were age, sex, level of social deprivation, and diabetes
duration. Area-based social deprivation was measured using the Scottish Index of Multiple Deprivation
(SIMD), with each individual assigned to a quintile of SIMD at baseline. SIMD is constructed from several
domains of area based deprivation; including income, education, housing, and crime (17). Consequently,
SIMD provides a high level overview of social deprivation but cannot be used to assess associations between
individual aspects of deprivation and health outcomes. Further adjustment was performed to account for
potential risk factors that had been observed to vary with SIMD quintile (ESM Figure 1) (18). Subsequent
fully adjusted models included annualised median HbA1c in categories previously used in (18), SIMD quintile,
use of continuous subcutaneous insulin infusion (CSII), completion of any level 3 (i.e. delivered in a group
setting) structured education course, the prescription of methadone (ATC = N07BC02), the prescription of
an antidepressant (ATC = N06A, N06CA). All covariates were time updated except for quintile of social
deprivation, which was only available at baseline. The risk factors for DKA events caused by delayed diagnosis
of diabetes may differ from those for DKA events following diagnosis. Consequently, we performed DKA
event rate regression analyses excluding DKA at diagnosis as sensitivity analysis. We also performed DKA
case-fatality regression sensitivity analyses restricted to only the deaths in which DKA was assigned as the
underlying cause on the associated MCCD.
Age-band stratified subgroup analyses were also performed to identify age specific associations between
covariates and DKA outcomes, with broad age-bands of <30, 30-59, and >59 used for this purpose.
We also calculated the annual percentage of individuals presenting with DKA at diagnosis of type 1 diabetes
over the study period and used a univariate Bayesian linear model to investigate the effect of calendar time
on the annual percentage change in this outcome. Further details of the statistical methods outlined here are
presented in the ESM methods.
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Results
Cohort Characteristics And Event Counts
We identified 37939 individuals with type 1 diabetes alive in Scotland at any point between 2004-01-01 and
2018-12-31. These individuals contributed a total of 393223 person-years to the study. 96.84 % of all possible
person time was observable. Over the study period, there were 30427 hospital admissions for DKA (which
occurred in 10397 individuals), of which 1490 were at the time of diagnosis with type 1 diabetes. There were
472 deaths in which DKA was present anywhere on a MCCD and 413 where DKA was the underlying cause
of death. These event counts correspond to a crude mortality rate of 120 and a crude DKA event rate of 7858,
per 100,000 person-years. 72.6 % of the cohort never had a hospital admission with DKA during the study
period, 15.1 % had one admission, and 12.3 % had multiple admissions. Of all deaths for which DKA was a
cause, 83.47 % occurred outside of a hospital admission. A detailed characterisation of the cohort at the time
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Figure 3. Directly Standardised DKA Mortality Rate
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Trends In DKA Outcomes Over The Study Period
There was a gradual increase in the standardised rate of DKA events across the study period, starting at
6182 events per 100,000 person years in 2004 and finishing at 8261 per 100,000 person years in 2018 (ESM
Figure 2). This pattern was seen in both sexes, and across SIMD quintiles (Figure 1), with the event rate in
the most deprived quintile increasing the most over the study period.
A non-linear relationship between standardised event rate and age was observed (Figure 2). Across all age
bands, the general trend over the study period has been toward increasing standardised DKA event rates.
The exception to this pattern was the reduction in event rate in the final years of the study period for 10-19
year olds. The association of calendar time with DKA event rates varied across broad age-bands (ESM Table
2), with DKA event rates increasing the least in individuals under 30 years of age (IRR = 1.044 [1.039-1.050]),
and increasing most rapidly in individuals aged 60 and above (IRR = 1.096 [1.081- 1.110]).
Rates of recurrent DKA increased over the study period (ESM Table 3). The rate of DKA at diagnosis was
13.35 % and this increased over the study period from 8.93% in 2004 to 17.68% in 2018, β = 0.57 [0.39-0.74]
(ESM Figure 3).
Directly standardised DKA mortality rates were 95 deaths per 100,000 person years in the first year of the
study period and 204 deaths per 100,000 person years in the final year. The annual directly standardised
mortality rate is presented in Figure 3, and the age-band specific directly standardised mortality rate is
presented in ESM Figure 4. The case-fatality rate over the entire study period was 1.53%, OR for year =
1.03 [1-1.05]. In age-band stratified analyses, evidence of an annual increase in case-fatality was identified for
individuals aged 30 and above only.
Risk Factors For DKA Outcomess
Age had a non-linear effect on DKA event rates (Table 1) and DKA recurrence rates (ESM Table 3), with
rates elevated in children, teenagers and younger adults and individuals aged 70+, as seen in the IRR for
each age band. Conversely, the effect of age on case fatality was linear (ESM Table 4).
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Table 1: DKA Event IRR Estimates Obtained With Multivariable Poisson Regression
Covariate IRR Q2.5 Q97.5 Approx. p-value
Year 1.058 1.054 1.061 <0.001
Age 1-10 Ref. - - -
Age 11-19 1.023 0.938 1.121 0.579
Age 20-29 0.649 0.591 0.713 <0.001
Age 30-39 0.399 0.361 0.441 <0.001
Age 40-49 0.329 0.296 0.366 <0.001
Age 50-59 0.312 0.278 0.350 <0.001
Age 60-69 0.320 0.282 0.365 <0.001
Age 70-79 0.476 0.412 0.550 <0.001
Age 80+ 0.780 0.653 0.933 0.007
Median HbA1c <7.5 %, <58 (mmol/mol) Ref. - - -
Median HbA1c 7.5-9.0 %, 58-75 (mmol/mol) 1.560 1.459 1.664 <0.001
Median HbA1c 9.1-10.0 %, 76-86 (mmol/mol) 2.801 2.621 2.995 <0.001
Median HbA1c >10.0 %, >86 (mmol/mol) 4.848 4.509 5.187 <0.001
Diabetes duration 0.984 0.982 0.986 <0.001
Male 0.814 0.776 0.855 <0.001
Female Ref. - - -
SIMD Quintile 1 (most deprived) Ref. - - -
SIMD Quintile 2 0.747 0.694 0.805 <0.001
SIMD Quintile 3 0.591 0.552 0.632 <0.001
SIMD Quintile 4 0.506 0.471 0.543 <0.001
SIMD Quintile 5 (least deprived) 0.446 0.406 0.490 <0.001
Current CSII therapy 0.792 0.731 0.858 <0.001
Current methadone prescription 1.468 1.234 1.747 <0.001
Current antidepressant prescription 1.474 1.428 1.522 <0.001
Completed a structured education course 0.841 0.787 0.898 <0.001
Male sex was associated with elevated DKA case fatality, but a lower DKA event rate and recurrence rate
IRR = 0.814 [0.776-0.855]. Age band stratified analyses showed that the association of male sex with elevated
DKA case-fatality was not present in the 60+ age-band (ESM Table 5).
Minimally adjusted analyses showed a clear association between level of social deprivation and DKA event
and recurence rate, although the association of increasing levels of social deprivation with case-fatality was
less consistent (ESM Table 6). The association of social deprivation with each DKA outcome in minimally
adjusted analyses was maintained after adjustment for further covariates. Higher HbA1c was associated with
elevated rates of DKA events and DKA recurence, but no association between the highest HbA1c category
and increased DKA case fatality was observed. Age-band stratified analyses did not support an association
between HbA1c category and case fatality (ESM Table 5). Prescription for an antidepressant and prescription
for methadone were both associated with elevated rates of each analysed DKA outcome. Age-band stratified
analyses supported the association of elevated DKA case fatality with antidepressant prescription in all
age-bands apart from the 0-29 age-band.
The use of CSII therapy or completion of a structured education course were both associated with reduced
rates of DKA events and reduced DKA recurence, but an association between these covariates and DKA
case-fatality could was not supported in these analyses. Age-band stratified analyses did not support the
association of CSII with reduced DKA event rates in the 30-59 age band. Similarly, age-band stratified
analyses did not support the association of CSII with reduced rates of recurrent DKA after the age of 29
(ESM Table 7), they also did not support the association of completion of structured education with reduced
rates of DKA below the age of 30.
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Sensitivity analyses showed that, apart from lowering the event rate in the youngest age band, excluding
DKA at diagnosis events from DKA event rate regression analysis did not meaningfully alter the association
between each covariate and DKA event rates (ESM Table 8). Excluding deaths for which DKA appeared on
the MCCD, but not as the underlying cause of death, resulted in no association between HbA1c category and
case-fatality being established (ESM Table 9).
Conclusions
Key Findings
Through the analysis of a national cohort of individuals with type 1 diabetes, we have identified patterns
in rates of DKA, and estimated the association of several risk factors with DKA outcomes. We identified
a gradual increase in DKA event rates, mortality rates, and DKA recurrence rates over the study period.
Increases in DKA event rates over time were identified across all age bands excluding individuals aged 10-19,
with rates for individuals aged 10-19 now similar to those of 20-29 year olds. The largest relative increase in
event rates was identified in individuals aged 60 or over. Age-band stratified regression analyses showed that
the greatest elevation in event rates over the study period were for individuals aged 60 years or older. These
results suggest that global increases in DKA admission rates could be partially driven by increases in DKA
rates in older individuals. The association of age with DKA case-fatality appears to be similar across all age
bands, suggesting that this association is linear and that DKA events are more likely to be fatal for older
individuals. The observation that older individuals are experiencing increasing rates of DKA, coupled with
DKA events being more likely to result in death for this age group is concerning.
Elevated HbA1c was associated with increased DKA event rates, and prescription for methadone and
antidepressants were both associated with considerably elevated DKA event and case-fatality rates. For some
covariates we found differences in the estimated effect on DKA event rates and case-fatality rates, suggesting
that the factors which elevate the risk of the occurrence of a DKA event may be different to the factors that
elevate the risk of an event being fatal. Completion of a structured education course and the use of CSII
were associated with reduced DKA event rates, but there was little evidence that completion of a structured
education course or CSII are associated with reduced case-fatality. We found that females experienced DKA
events at a higher rate than males, but a given DKA event was more likely to be fatal for males. A potential
contributing factor in elevated DKA rates for females in Scotland is elevated HbA1c, which has been observed
in this subgroup in a previous study (18).
Associations between social deprivation and mortality or morbidity in type 1 diabetes have previously been
identified in Scotland (18–20). The association of social deprivation with DKA outcomes is supported by the
results presented here. Adjustment for several covariates suggests that this association occurs independently of
HbA1c, which is higher on average in more socially deprived areas (18), and CSII or completion of structured
education, which are less prevalent in more deprived areas (ESM Figure 1). This suggests that factors other
than those included in these models contribute to the elevated DKA rates observed in more socially deprived
areas.
Comparison To Previous Literature
Increases in DKA admission rates have been identified in England, Wales, Australia and New Zealand,
Denmark, and the United States (21–25), although reductions in DKA admission rates have been observed
in Italy and Taiwan (26,27). A lower threshold for hospital admission, prevalence of basal-bolus insulin
regimes, and alterations to DKA diagnositic criteria have all been proposed as potential contributors to
increasing DKA rates (23,25). The reduction in DKA event rates for 10-19 year olds in the final years of our
study period represents a deviation from the general trend of increasing DKA rates. While the cause of this
reduction has not been established by these analyses, across a similar time period these younger individuals
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experienced the greatest improvement in HbA1c and the widest initiation of CSII amongst all individuals
with type 1 diabetes in Scotland (18).
We found that the rate at which individuals presented with DKA at the time of diagnosis increased over
the study period, but the absolute rate did appear to be comparatively low. A recent study found that the
prevalence of DKA at diagnosis in children with type 1 diabetes ranged from 18.4% to 53.2% across a number
of different nations (13), whereas the annual prevalence reported here, amongst both children and adults ,
never exceeded 17.68 %.
There are few published studies focusing on DKA mortality rates in large cohorts (3), making it difficult to
compare the mortality trends identified here to other populations. Another study using the Scottish diabetes
register found that DKA mortality rates in individuals under the age of 50 had not significantly reduced in
the period 2004 to 2017 (11). The results presented here demonstrate that this trend is also observed when
this population is extended to include individuals aged 50 and over.
One previous study found that CSII therapy was not associated with a significant decrease in DKA admission
rates (6). Conversely, the results presented here and by Jeyam et al. (28) suggest that CSII therapy is
associated with reduced DKA event rates. Other studies have demonstrated that structured education courses
are associated with lower rates of DKA admission (15,16), and our results provide further observational
evidence to support this association across all age groups. Similarly, previously observed associations between
recurrent DKA and antidepressant use, social deprivation, or higher HbA1c (9) are supported by our results.
Strengths And Limitations
A strength of these analyses was the use of a national level cohort with almost complete coverage of all
individuals with type 1 diabetes. The follow-up of these individuals was extensive, with only a small percentage
of possible person-time being unobserved. One potential weakness in the construction of outcomes in these
analyses was the lack of confirmation of DKA through biochemical tests. However, an evaluation of DKA
discharge coding for a Scottish cohort (2002-2009) found that the sensitivity of SMR data is adequate for
epidemiological study (29). It is possible that changes in DKA diagnosing and discharge coding practices
over the study period have contributed to increasing rates of DKA, although a simultaneous increase in DKA
mortality rate suggests that any such change is unlikely to be driving the observed DKA event rate increases.
Generalisation of the results presented here to other countries is likely to be limited by the fact that Scotland
has universal healthcare that is free at the point of use with free access to prescribed medications, including
insulin. There is also potential allocation bias associated with CSII referral and initiation in Scotland (30),
meaning that a causal relationship between CSII and DKA outcomes cannot be established in these analyses.
While we included prescription for antidepressants and methadone as covariates in these analyses, their
accuracy as markers for depression and opioid dependence is limited by certain antidepressants being indicated
for the treatment of neuropathy and methadone being indicated for the treatment of severe pain. A further
potential weakness of using methadone prescription as a marker for opioid dependence is that this approach
will not capture individuals with opioid dependence who did not receive a methadone prescription. Despite
this potential wekaness, we still observed a consitent association between methadone prescription and elevated
DKA event rates and mortality.
Policy Implications And Future Work
The significant contribution of DKA to excess mortality means that prevention of this acute complication
should remain a priority, particularly as DKA rates are rising. The association of social deprivation with DKA
outcomes suggests that more work is required to reduce rates of DKA in people living in more deprived areas.
Mair et al. (18) identified higher HbA1c in people living in more socially deprived areas in Scotland, and here
we demonstrate the consistent association of high HbA1c with DKA event and recurrence rates. Similarly,
while CSII therapy and structured education completion are associated with lower DKA event and recurrence
rates, they have lower cumulative incidence amongst people living in more deprived areas (ESM Figure 1).
Consequently, improved glycaemic control, more widespread usage of CSII, and completion of structured
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education may improve DKA outcomes for people living in the most deprived areas. The association of social
deprivation with DKA event rate is still significant after adjustment for several confounders, this suggests
that socioeconomic factors not included in these models play a key role in DKA event rates for people living
in more socially deprived areas. Future work must identify these factors and establish effective interventions
to reduce health inequalities. Furthermore, as the prevalence of CSII increases, future work must assess rates
of DKA as a consequence of CSII failure, particularly following initiation of treatment (31).
Drug-related deaths in the general population in Scotland have risen over the previous 25 years (32). Whilst
the association of methadone prescription with elevated DKA rates has been established here, methadone is
only implicated in approximately 44% of all drug-related deaths in Scotland, with 94% of all drug-related
deaths involving multiple substances. Consequently more work is required to investigate the broader effect of
drug misuse on DKA admission and mortality in Scotland, particularly as DKA mortality rates have increased
in the same age groups in which drug-related deaths in the general population have increased the most.
More studies utilising electronic healthcare records are required to accurately quantify the incidence of DKA
in other countries and to identify the underlying causes of the association of each risk factor with DKA
outcomes (5,33). Of particular concern are the causes of the association of social deprivation with DKA and
whether the higher rate of DKA in young females is influenced by the prevalence of disordered eating in this
group (10,34).
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Figure Captions
• Figure 1 - Directly standardised diabetic ketoacidosis (DKA) event rate over the study period, separated
into quintiles of social deprivation. Vertical lines represent 95% confidence intervals for the standardised
rate. There is a clear social deprivation effect that is maintained across the study period.
• Figure 2 - Directly standardised diabetic ketoacidosis (DKA) event rate over the study period, separated
in to 10 year age bands. Vertical lines represent 95% confidence intervals for the standardised rate.
The general trend in DKA event rates over the study period appears to vary by age band, with 10-19
year olds experiencing a reduction in DKA rate across the study period and other bands experiencing
varying degrees of an increase in DKA event rate.
• Figure 3 - Directly standardised diabetic ketoacidosis (DKA) mortality rate over the study period,
separated by sex and also calculated for both males and females jointly. Vertical lines represent 95%
confidence intervals for the standardised rate. Over the course of the study period there has been a
general trend toward an increase in DKA mortality rates.
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